SCHEMBL315734

SCHEMBL315734

[NH]C1=NCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367035 0.82
SCHEMBL3742115 0.67 NISCH (0.56)
SCHEMBL906548 0.63 ADRA2A (0.40)
SCHEMBL906626 0.63
SCHEMBL5476725 0.63 NISCH (0.79)
SCHEMBL1202841 0.63
SCHEMBL11563018 0.62
SCHEMBL2288651 0.62
SCHEMBL3957418 0.62
SCHEMBL16730 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP claimed
CN-109311889-B Activin receptor-like kinase inhibitors 缆图药品公司 2021-11-16 CN claimed
US-20210251961-A1 COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME ALLERGAN INC (US) 2021-08-19 US claimed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 EP claimed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO claimed
US-20150368236-A1 2-(PYRIDIN-3-YL)-5-HETARYL-THIAZOLE COMPOUNDS CARRYING AN IMINE OR IMINE-DERIVED SUBSTITUENT FOR COMBATING INVERTEBRATE PESTS BASF SE (DE) 2015-12-24 US claimed
US-8455492-B2 Methods for treating retinal diseases ALLERGAN, INC. (US) 2013-06-04 US claimed
EP-1611891-B1 Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury ALLERGAN INC (US) 2012-08-22 EP claimed
US-20110183946-A1 Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) 2011-07-28 US claimed
EP-0835110-B2 USE OF (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN TREATING OCULAR NEURAL INJURY ALLERGAN INC (US) 2011-06-15 EP claimed
WO-1992004345-A1 6- or 7- (2-IMINO-2-IMIDAZOLIDINE)-1,4-BENZOXAZINES AS ALPHA ADRENERGIC AGENTS ALLERGAN, INC. (US) 1992-03-19 WO claimed
US-5091528-A Antiglaucoma, antidiarrhea agents, diuretics, vasoconstrictors ALLERGAN, INC. (US) 1992-02-25 US claimed
WO-1992002515-A1 (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS FOR USING SAME ALLERGAN, INC. (US) 1992-02-20 WO claimed
WO-1992002513-A1 HETEROCYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-20 WO claimed
US-5077292-A Gastrointestinal disordes; kidney and vision defects ALLERGAN, INC. (US) 1991-12-31 US claimed
US-5021416-A Glaucoma ALLERGAN, INC. (US) 1991-06-04 US claimed
EP-0426390-A2 Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure ALLERGAN, INC. (US) 1991-05-08 EP claimed
EP-0422878-A1 (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same ALLERGAN, INC. (US) 1991-04-17 EP claimed
US-4436913-A HYPOTENSIVE AGENTS SIEGFRIED AKTIENGESELLSCHAFT (CH) 1984-03-13 US claimed
EP-0070084-A2 Imidazoline derivatives BEECHAM GROUP PLC (GB) 1983-01-19 EP claimed